|
 |
Vascular Disease > Sepsis
The following information is about Sepsis.
Sepsis Defined
The presence of infection-causing organisms in the blood.
This definition is in context to Vascular Disease. See more contextual defintions for Sepsis.
ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
Published September 3, 2008, 9:24 am, Centre Daily Times
ImClone Systems Incorporated (NASDAQ: IMCL) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) to broaden the use of ERBITUX(R) (cetuximab) to include first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The application, submitted on August 29, 2008, was prepared in conjunction ...
ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
Published September 3, 2008, 9:00 am, Business Wire via Yahoo! Finance
NEW YORK----ImClone Systems Incorporated today announced that it has submitted an application to the U.S. Food and Drug Administration to broaden the use of ERBITUX® to include first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck .
ATEL Ventures Portfolio Company, Adenosine Therapeutics to be Acquired by Clinical Data, Inc.
Published September 3, 2008, 6:25 am, Centre Daily Times
ATEL Ventures, a leading provider of secured financing to emerging growth companies, is pleased to announce that Clinical Data, Inc. has entered into an agreement to acquire Adenosine Therapeutics, an ATEL portfolio company. Clinical Data (Nasdaq:CLDA) paid $11 million in cash, and entered into a $22 million, five-year promissory note and a separate $3.2 million, 32-month promissory note to ...
PRESS RELEASE: ATEL Ventures Portfolio Company, Adenosine Therapeutics to be Acquired by Clinical Data, Inc.
Published September 2, 2008, 3:52 pm, Nasdaq
ATEL Ventures Portfolio Company, Adenosine Therapeutics to be Acquired by Clinical Data, Inc. SAN FRANCISCO--(BUSINESS WIRE)--September 02, 2008-- ATEL Ventures, a leading provider of secured financing to emerging growth companies, is pleased to announce that Clinical Data, Inc. has entered into an agreement to acquire Adenosine Therapeutics, an ATEL portfolio company.
ATEL Ventures Portfolio Company, Adenosine Therapeutics to be Acquired by Clinical Data, Inc.
Published September 2, 2008, 3:26 pm, Business Wire via Yahoo! Finance
SAN FRANCISCO----ATEL Ventures, a leading provider of secured financing to emerging growth companies, is pleased to announce that Clinical Data, Inc. has entered into an agreement to acquire Adenosine Therapeutics, an ATEL portfolio company.
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
Published September 1, 2008, 5:10 am, Medical News Today
ImClone Systems Incorporated (NASDAQ: IMCL) announced overall survival results from BMS CA225-099 (BMS-099), an open-label Phase 3 study of ERBITUX® (cetuximab) in combination with a taxane and carboplatin in the first-line treatment of all histological subtypes of advanced non-small cell lung cancer (NSCLC).
Are you looking for additional Vascular Disease > Sepsis news? Try our new "Sepsis News Focus" area.
Off-site Sepsis Links, User Submitted
The following links have been collected through user bookmark submission in the Sepsis category. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.
Fri Sep 5
- JAMA | High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Tria (KyberSept Trial)
- Coagulation Abnormalities in Critically Ill Patients | Stephen M Opal, MD and Marcel A Levi, MD
- Blood Disorders | Disseminated Intravascular Coagulation | GOGR.ORG
Thu Sep 4
- Straight Talk on Sepsis from the ISICEM
- How, oh HOW!? Does Someone Get SEPSIS in the Hospital? :::::..... Society of Critical Care Medicine
- Sepsis: What You Should Know | Surviving Sepsis Campaign
- eMedicine :::... Disseminated Intravascular Coagulation : Article by Marcel M Levi
Wed Sep 3
- Escherichia coli Sepsis and Ampicillin Resistance in Neonates: his study consisted of a review of data from infants with Escherichia coli sepsis who received care at one US hospital from 1979 to 2006, with the goal of determining how E coli resistance to ampicillin may change as more infants are exposed to intrapartum antibiotics. The study authors noted that E coli has begun to replace Group B Streptococcus as the predominant organism in "early-on set sepsis" (EOS) in the first 72 hours of life. This study looked at pathogens in both EOS and "late-ons et sepsis" (LOS) -- sepsis that takes place after 72 hours of life-- -- with an emphasis on the susceptibility patterns of E coli isolates across the 28-year time period.
Mon Aug 18
Sun Aug 17
- NEJM -- Hydrocortisone Therapy for Patients with Septic Shock - The CORTICUS Trial by Sprung et.al.: Conclusions Hydrocortisone did not improve survival or reversal of shock in patients with septic shock, either overall or in patients who did not have a response to corticotropin, although hydrocortisone hastened reversal of shock in patients in whom shock was reversed.
If you would like to find additional social bookmark based links on the topic of we recommend the Open Tag Directory > Sepsis. If you would like to find related tags we recommend Tag Patterns > Sepsis
Off-site Sepsis Research Links
If you still need additional information on Sepsis then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.
Vascular Disease Topics
Everything you need to know about Vascular Disease
Vascular Disease
If you know the Vascular Disease Term Name use the links below to quickly jump to your desired focus.
Bookmark Us
The On Topic Network
This website is part of The On Topic Network.
Thank You
Vascular-Disease.On-Topic.net was developed by Odin Metatech, Inc and runs on the Odin Assemble platform.
Best Viewed With
License
This work is licensed under Creative Commons.